Sarah A Wall, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Cancer Control
About Me
More info forI am a hematologist who specializes in treating patients with blood cancers, such as leukemia, myelodysplastic syndromes and myelofibrosis. My area of focus is geriatrics (i.e., the effect of age on blood cancer diagnosis and treatment), as well as blood and marrow transplantation. Every patient is a person with family and friends and a life that has just been turned upside down by a diagnosis they never saw coming, and I am honored to fight alongside them and contribute to the continued growth and improvement in treatment options for their disease. At The James, we prioritize patient-centered care. This not only means identifying targets within an individual patient’s cancer cells that may be amenable to immune therapy, but it also includes our approach to each patient as a unique individual. Patients are supported by a team that includes advanced practice providers, nurses, patient care associates (PCAs), patient care resource managers (PCRMs), social workers and schedulers. I also see patients in our Cancer and Aging Resiliency (CARE) clinic, where we utilize an interdisciplinary team, including physiotherapists, audiologists, pharmacists, dieticians, nurses and case managers. This team approach affords us a more comprehensive method to patient care, with an emphasis on treating the patient rather than just the cancer itself. As a member of the Cancer Control Program at the OSUCCC – James, my research interests include pre-transplant assessment for older adults undergoing allogeneic transplant, treatment decision-making in older adults with hematologic malignancies, coordination of care with referring community providers, and the impact of aging on immune function. In addition to my clinical and research work, I am an assistant professor in the Division of Hematology at The Ohio State University College of Medicine and an active member of several organizations, including the International Society of Geriatric Oncology, the Cancer and Aging Research Group, the American Society of Hematology and the American Society of Clinical Oncology. One of the great things about working at the OSUCCC – James are the relationships that I have formed with so many experts in my own field and other complementary fields. I am constantly reminded of the quote, “If you want to go fast, go alone. If you want to go far, go together.” And it’s exactly this collaborative effort that’s at the heart of The James as we strive to create a cancer-free world.
Clinical Expertise
More info for- Myelodysplastic Syndromes
- Graft vs Host Disease
- Acute Myeloid Leukemias
- Geriatrics
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Internal Medicine
- Riverside Methodist Hospital
3535 Olentangy River Rd, Columbus, OH
Residency - Internal Medicine
- Riverside Methodist Hospital
3535 Olentangy River Rd, Columbus, OH
Medical School
- University of Toledo College of Medicine
3000 Arlington Ave, Toledo, OH
- Ohio State University Wexner Medical Center
Academic Office & Contact Information
More info forAcademic Office:
The James Outpatient Care 7226
2121 Kenny Rd
Columbus, Ohio 43221Email:
fortier.14@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 12, 2024Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
Caputo J, Peddireddi A, Bhatta S, Huang Y, Bezerra E, Brammer J, Larkin K, Mims A, Vasu S, Wall S, Choe H
Leuk Lymphoma
September 12, 2024Proceedings of the 2024 Third Annual ASTCT-NMDP ACCESS Initiative Workshop.
Auletta JJ, Holter-Chakrabarty J, Munshi P, Wall S, Khera N, Knutson J, Gomez-Arteaga A, Hall AG, Foster J, Ruffin A, Robb D, Nemecek E, Rouce R, Davies SM, ACCESS Workshop Team Members
Transplant Cell Ther
June 12, 2024Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, William B, Penza S, Benson DM, Efebera YA, Sharma N
Leuk Lymphoma
June 1, 2024NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.
Gotlib J, Gerds AT, Abdelmessieh P, Ali H, Castells M, Dunbar A, Fein Revell R, George TI, Green S, Gundabolu K, Hexner E, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, Manchanda N, Masarova L, May J, McMahon B, Mohan SR, Nadiminti KV, Oh S, Palmer J, Patel A, Patel AA, Podoltsev N, Rein L, Salit R, Talpaz M, Wadleigh M, Wall S, Bergman MA, Hochstetler C
J Natl Compr Canc Netw
May 30, 2024Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.
Risch Z, Kaffenberger BH, Chung CG, Samorodnitsky E, Hoskins EL, Dao T, Smith A, Wall SA, Brammer J, Reeser JW, Wing MR, Hopkins JF, Albacker LA, Abruzzo LV, Eisele CD, Freud AG, Roychowdhury S, Walsh KE
Haematologica
November 28, 2023Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants.
Karpen R, Sen J, Wall S, Musson S, Tossey J
Leuk Res
September 23, 2023Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
Jamy OH, Kasner M, Wall S, Ingram S, Dent D', Dudley WN, Dudley L, Scott JM, Wujcik D
Leuk Res
July 6, 2023Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.
Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Tamari R, Grunwald MR, Abedin S, Nadiminti KV, Iqbal M, Gerds AT, Viswabandya A, McCurdy SR, Al Malki MM, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S
Haematologica
May 1, 2023The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients.
Wall SA, Olin R, Bhatt V, Chhabra S, Munshi P, Hacker E, Hashmi S, Hassel H, Howard D, Jayani R, Lin R, McCurdy S, Mishra A, Murthy H, Popat U, Wood W, Rosko AE, Artz A
Transplant Cell Ther
November 14, 2022Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Cancers (Basel)
September 1, 2022Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C
J Natl Compr Canc Netw
February 14, 2022Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.
Elkrief A, Hennessy C, Kuderer NM, Rubinstein SM, Wulff-Burchfield E, Rosovsky RP, Vega-Luna K, Thompson MA, Panagiotou OA, Desai A, Rivera DR, Khaki AR, Tachiki L, Lynch RC, Stratton C, Elias R, Batist G, Kasi A, Shah DP, Bakouny Z, Cabal A, Clement J, Crowell J, Dixon B, Friese CR, Fry SL, Grover P, Gulati S, Gupta S, Hwang C, Khan H, Kim SJ, Klein EJ, Labaki C, McKay RR, Nizam A, Pennell NA, Puc M, Schmidt AL, Shahrokni A, Shaya JA, Su CT, Wall S, Williams N, Wise-Draper TM, Mishra S, Grivas P, French B, Warner JL, Wildes TM, COVID-19 and Cancer Consortium
Lancet Healthy Longev
January 13, 2022Multidisciplinary Approach to Older Adults with Hematologic Malignancies-a Paradigm Shift.
Wall SA, Stevens E, Vaughn J, Bumma N, Rosko AE, Borate U
Curr Hematol Malig Rep
January 1, 2022Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.
Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Front Oncol
October 28, 2021Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR
Hematol Oncol
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Wall has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- MorphoSys
- Cardinal Health
- Sobi
Patient Comments
Dr. Wall is an amazing and very empathetic doctor. I highly recommend her if you are discussing/needing stem cell/bone marrow transplant.
Dr. Wall and her staff are the best.
Dr. Wall is just outstanding. She knows everything about me & my condition and I have complete trust and faith in her expertise treating me. She is the best!
Doctor Wall always gives me her undivided attn and never feels like she is rushing even though she is very busy.
Dr. Wall spent lot of time discussing my condition and treatment
Very informative
They listen very well and very concerned about the best interest of my health
Dr Wall has always been very thorough to explain the lab findings a d to answer any questions. She always leaves me with positive thoughts. She is the best!!
My care provider Dr. Wall and her staff answered every question I had. They put me in with all the resources I need
The team kept me very well informed. And answered my questions.